Abbott Laboratories with price, financials, news flow, and insider context in one page.
Abbott Laboratories is being tracked here through price action, operating context, and headline flow. This public page covers the latest market move, where ABT sits inside Healthcare and Medical Devices, and the key financial markers that matter before moving into a fuller research workflow.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
This page is structured for research context, not a trade call. It gives you a clean read on where ABT sits in its range, what the last few quarters look like, and which headlines are shaping attention.
For position sizing, alerts, saved watchlists, and deeper analysis workflows, the next step is the logged-in Meridian workspace.
| Quarter | Revenue | Net income | Free cash flow |
|---|---|---|---|
| Q1 2026 | 11.16B | 1.08B | 916M |
| Q4 2025 | 11.46B | 1.78B | 2.63B |
| Q3 2025 | 11.37B | 1.64B | 2.29B |
| Q2 2025 | 11.14B | 1.78B | 1.55B |
This is Goldman's second downward revision in a week, which gives the cuts additional weight as a directional signal rather than a knee-jerk reaction. The bring-forward of Persian Gulf export norma...
On Monday, the Dow Jones Industrial Average climbed to new intraday and closing records on a potential deal between the U.S. and Iran.
See the next report date, earnings cadence, and reporting context.
Open a side-by-side comparison page to frame valuation and growth.
Read open desk notes tied to sectors, macro themes, and active names.
Learn the framework behind valuation, momentum, and risk before you act.
Abbott Laboratories (ABT) — questions investors ask
What is the current stock price of Abbott Laboratories (ABT)?
Abbott Laboratories (ABT) is trading at $88.67, up 0.56% in the latest session. The live price and one-year chart on this page update through the trading day.
What is Abbott Laboratories's market capitalization?
Abbott Laboratories has a market capitalization of about 154.45B, derived from the latest share price and shares outstanding.
When is Abbott Laboratories's next earnings date?
Abbott Laboratories is next expected to report earnings on Jul 16, 2026. The ABT earnings page tracks the estimate and reporting history.
What is Abbott Laboratories's P/E ratio?
Abbott Laboratories trades at a forward price-to-earnings ratio of 14.63 — one measure of how the market is pricing its future earnings.
What is ABT's 52-week trading range?
Over the past 52 weeks, ABT has traded between $81.97 and $139.06.
What sector is Abbott Laboratories in?
Abbott Laboratories operates in the Healthcare sector, within the Medical Devices industry.
Does Abbott Laboratories pay a dividend?
Abbott Laboratories currently carries a dividend yield of about 100.0%.
What is the analyst price target for ABT?
The mean analyst price target for ABT is $116.54, with an overall analyst view of Buy.
A public stock page should answer the first research questions before asking for a signup.
This ABT page is designed for public research utility. You can read the latest session move, check the one-year chart, review a compact financial table, scan recent headlines, and compare adjacent names without immediately moving into a gated dashboard.
The logged-in Meridian workflow goes further with saved watchlists, deeper analysis, alert routing, and recurring review systems. The public layer is meant to be credible and indexable on its own, not a hollow teaser page.